Product Pathways - Wnt / Hedgehog / Notch
TCF4 (C9B9) Rabbit mAb #2565
| Applications | Reactivity | MW (kDa) | Source | Isotype |
|---|---|---|---|---|
| W IP IF-IC | H (M) (R) | 58, 79 | Rabbit | IgG |
Applications Key:
W=Western Blotting
IP=Immunoprecipitation
IF-IC=Immunofluorescence (Immunocytochemistry)
Reactivity Key:
H=Human
M=Mouse
R=Rat
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.
Specificity / Sensitivity
TCF4 (C9B9) Rabbit mAb detects endogenous levels of total TCF4 protein.
Source / Purification
Monoclonal antibodies are produced by immunizing rabbits with a synthetic peptide (KLH-coupled) corresponding to residues surrounding Glu81 of human TCF4.
Background
LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors which consists of the following: Lymphoid enhancer factor 1 (LEF1), T Cell Factor 1 (TCF1), TCF3 and TCF4 (1). LEF1 and TCF1 were originally identified as important factors regulating early lymphoid development (2) that act downstream in Wnt signaling. LEF1/TCF bind to Wnt response elements to provide a docking site for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1/TCF proteins are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).
TCF4, also known as TCF7L2, is expressed widely during development. Gene targeting studies indicate that TCF4 is required to maintain the crypt stem cells of the small intestine (6,7). TCF4 has several slicing isoforms which are expressed differentially in tissues and during cancer progression (8,9). Studies also indicate that a variant of the TCF4 gene confers an increased risk of type 2 diabetes (10).
- Waterman, M.L. (2004) Cancer Metastasis Rev. 23, 41-52.
- Schilham, M.W. and Clevers, H. (1998) Semin. Immunol. 10, 127-132.
- Brantjes, H. et al. (2002) Biol. Chem. 383, 255-261.
- Reya, T. and Clevers, H. (2005) Nature 434, 843-850.
- Logan, C.Y. and Nusse, R. (2004) Annu. Rev. Cell Dev. Biol. 20, 781-810.
- Cho, E.A. and Dressler, G.R. (1998) Mech. Dev. 77, 9-18.
- Korinek, V. et al. (1998) Nat. Genet. 19, 379-383.
- Howng, S.L. et al. (2004) Int. J. Oncol. 25, 1685-1692.
- Shiina, H. et al. (2003) Clin. Cancer Res. 9, 2121-2132.
- Grant, S.F. et al. (2006) Nat. Genet. 38, 320-323.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 2566 TCF4 Antibody
- 2286 LEF1 (C18A7) Rabbit mAb
- 9581 β-Catenin Antibody (Amino-terminal Antigen)
- 9587 β-Catenin Antibody (Carboxy-terminal Antigen)
- 3216 Dvl2 Antibody
- 3224 Dvl2 (30D2) Rabbit mAb
- 3218 Dvl3 Antibody
- 9315 GSK-3β (27C10) Rabbit mAb
- 2568 Phospho-LRP6 (Ser1490) Antibody
- 2560 LRP6 (C5C7) Rabbit mAb
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide